PrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system.
dc.contributor.author | Alonso Alconada, Lorena | |
dc.contributor.author | Barbazan, Jorge | |
dc.contributor.author | Candamio, Sonia | |
dc.contributor.author | Falco, Josep Lluis | |
dc.contributor.author | Antón Rodríguez, Cristina | |
dc.contributor.author | Martín Saborido, Carlos | |
dc.contributor.author | Fuster, Gustavo | |
dc.contributor.author | Sampedro, Mabel | |
dc.contributor.author | Grande, Carlos | |
dc.contributor.author | Lado, Rubén | |
dc.contributor.author | Sampietro Colom, Laura | |
dc.contributor.author | Crego, Eladio | |
dc.contributor.author | Figueiras, Sergio | |
dc.contributor.author | León Mateos, Luis | |
dc.contributor.author | López López, Rafael | |
dc.contributor.author | Abal, Miguel | |
dc.date.accessioned | 2017-11-17T07:56:29Z | |
dc.date.available | 2017-11-17T07:56:29Z | |
dc.date.issued | 2017 | |
dc.description.abstract | Purpose: Management of metastatic disease in oncology includes monitoring of therapy response principally by imaging techniques like CT-Scan. In addition to some limitations, the irruption of liquid biopsy and its application in personalized medicine has encouraged the development of more efficient technologies for prognosis and follow-up of patients in advanced disease. Methods: PrediCTC constitutes a panel of genes for the assessment of Circulating Tumor Cells (CTC) in metastatic colorectal cancer patients, with demonstrated improved efficiency compared to CT-Scan for the evaluation of early therapy response in a multicenter prospective study. In this work, we designed and developed a technology transfer strategy to define the market opportunity for an eventual implementation of PrediCTC in the clinical practice. Results: This included the definition of the regulatory framework, the analysis of the regulatory roadmap needed for CE mark, a benchmarking study, the design of a product development strategy, a revision of intellectual property, a cost-effectiveness study and an expert panel consultation. Conclusion: The definition and analysis of an appropriate technology transfer strategy and the correct balance among regulatory, financial and technical determinants are critical for the transformation of a promising technology into a viable technology, and for the decision of implementing liquid biopsy in the monitoring of therapy response in advanced disease. | spa |
dc.description.extent | 533 KB | spa |
dc.identifier.issn | 1699-3055 | |
dc.identifier.uri | http://hdl.handle.net/10641/1365 | |
dc.language.iso | eng | spa |
dc.publisher | Clinical and Translational Oncology | spa |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.rights.accessRights | open access | spa |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | Liquid biopsy | spa |
dc.subject | Metastatic colorectal cancer | spa |
dc.subject | Regulatory roadmap | spa |
dc.subject | Benchmarking | spa |
dc.subject | Product development | spa |
dc.subject | Intellectual property | spa |
dc.subject | Cost-effectiveness | spa |
dc.subject | Expert panel | spa |
dc.title | PrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system. | spa |
dc.type | journal article | spa |
dc.type.hasVersion | SMUR | spa |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 72b2ac96-de6b-4634-aede-647e87a82b46 | |
relation.isAuthorOfPublication | 1bde2976-5689-4b4e-b24a-ef0d66b7cf6b | |
relation.isAuthorOfPublication.latestForDiscovery | 72b2ac96-de6b-4634-aede-647e87a82b46 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Alonso-ALconada et al., Revised Manuscript CLAT-D-17-00439.pdf
- Size:
- 532.7 KB
- Format:
- Adobe Portable Document Format